Search Results

There are 24391 results for: content related to: Erratum

  1. You have full text access to this Open Access content
    Myocardial changes after spironolactone in spontaneous hypertensive rats. A laser scanning confocal microscopy study

    Journal of Cellular and Molecular Medicine

    Volume 6, Issue 1, January 2002, Pages: 49–57, Leila Maria Meirelles Pereira and C.A. Mandarim-de-Lacerda

    Version of Record online : 1 MAY 2007, DOI: 10.1111/j.1582-4934.2002.tb00310.x

  2. Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patents

    Clinical Pharmacology & Therapeutics

    Volume 27, Issue 4, April 1980, Pages: 533–543, L E Ramsay, J Hettiarachchi, R Fraser and J J Morton

    Version of Record online : 16 APR 1980, DOI: 10.1038/clpt.1980.75

  3. You have free access to this content
    Spironolactone is More Effective Than Eplerenone at Lowering Blood Pressure in Patients With Primary Aldosteronism

    The Journal of Clinical Hypertension

    Volume 13, Issue 8, August 2011, Pages: 629–631, Michael J. Bloch and Jan N. Basile

    Version of Record online : 14 JUL 2011, DOI: 10.1111/j.1751-7176.2011.00495.x

  4. HYPERKALEMIC CHANGES DURING SPIRONOLACTONE THERAPY FOR CIRRHOSIS AND ASCITES, WITH SPECIAL REFERENCE TO HYPERKALEMIC INTERMITTENT PARALYSIS

    Journal of the American Geriatrics Society

    Volume 16, Issue 8, August 1968, Pages: 874–886, János P. Radó, Judit Marosi, László Szende and József Takó

    Version of Record online : 27 APR 2015, DOI: 10.1111/j.1532-5415.1968.tb02682.x

  5. You have free access to this content
    Safety of Spironolactone Use in Ambulatory Heart Failure Patients

    Clinical Cardiology

    Volume 31, Issue 11, November 2008, Pages: 509–513, Ricardo J. Lopes, Ana Patricia Lourenço, Joana Mascarenhas, Ana Azevedo and Paulo Bettencourt

    Version of Record online : 12 NOV 2008, DOI: 10.1002/clc.20284

  6. Comparison of electrospun and extruded soluplus®-based solid dosage forms of improved dissolution

    Journal of Pharmaceutical Sciences

    Volume 101, Issue 1, January 2012, Pages: 322–332, Zsombor K. Nagy, Attila Balogh, Balázs Vajna, Attila Farkas, Gergő Patyi, Áron Kramarics and György Marosi

    Version of Record online : 23 AUG 2011, DOI: 10.1002/jps.22731

  7. Spironolactone and canrenoate-K: Relative potency at steady state

    Clinical Pharmacology & Therapeutics

    Volume 21, Issue 5, May 1977, Pages: 602–609, Lawrence Ramsay, Michael Asbury, John Shelton and Ian Harrison

    Version of Record online : 4 JAN 2016, DOI: 10.1002/cpt1977215602

  8. New insights into the pharmacokinetics of spironolactone

    Clinical Pharmacology & Therapeutics

    Volume 38, Issue 4, October 1985, Pages: 469–474, Hans W P M Overdiek, Walter A J J Hermens and Frans W H M Merkus

    Version of Record online : 15 OCT 1985, DOI: 10.1038/clpt.1985.206

  9. The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception

    European Journal of Pain

    Volume 18, Issue 3, March 2014, Pages: 386–395, T.O. Lilius, V. Jokinen, M.S. Neuvonen, A.J. Väänänen, M. Niemi, P.V. Rauhala and E.A. Kalso

    Version of Record online : 30 JUL 2013, DOI: 10.1002/j.1532-2149.2013.00371.x

  10. You have free access to this content
    Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial

    European Journal of Heart Failure

    Volume 10, Issue 2, February 2008, Pages: 157–163, R.A.P. Weir, John J.V. McMurray, Margareta Puu, Scott D. Solomon, Bertil Olofsson, Christopher B. Granger, Salim Yusuf, Eric L. Michelson, Karl Swedberg, Marc A. Pfeffer and CHARM Investigators

    Version of Record online : 13 JAN 2014, DOI: 10.1016/j.ejheart.2007.12.006

  11. You have free access to this content
    Spironolactone inhibition of contraction and calcium channels in rat portal vein

    British Journal of Pharmacology

    Volume 92, Issue 3, November 1987, Pages: 535–544, C. Dacquet, G. Loirand, C. Mironneau, J. Mironneau and P. Pacaud

    Version of Record online : 19 JUL 2012, DOI: 10.1111/j.1476-5381.1987.tb11354.x

  12. Activity of sulfur-containing intermediate metabolites of spironolactone

    Clinical Pharmacology & Therapeutics

    Volume 27, Issue 3, March 1980, Pages: 363–369, Gordon T McInnes, Michael J Asbury, John R Shelton, Ian R Harrison, Lawrence E Ramsay, Geoffrey R Venning and Joan M Clarke

    Version of Record online : 21 MAR 1980, DOI: 10.1038/clpt.1980.48

  13. STUDIES ON THE METABOLIC EFFECTS OF SPIRONOLACTONE IN MAN

    Annals of the New York Academy of Sciences

    Volume 88, Issue 4, October 1960, Pages: 864–880, W. Guy Hood Jr., S. Richardson Hill Jr., James A. Pittman Jr. and T. Albert Farmer Jr.

    Version of Record online : 15 DEC 2006, DOI: 10.1111/j.1749-6632.1960.tb20077.x

  14. Water-soluble β-Cyclodextrins in Paediatric Oral Solutions of Spironolactone: Preclinical Evaluation of Spironolactone Bioavailability from Solutions of β-Cyclodextrin Derivatives in Rats

    Journal of Pharmacy and Pharmacology

    Volume 50, Issue 6, June 1998, Pages: 611–619, ANN M. KAUKONEN, HANS LENNERNÄS and JUKKA-PEKKA MANNERMAA

    Version of Record online : 12 APR 2011, DOI: 10.1111/j.2042-7158.1998.tb06894.x

  15. You have free access to this content
    Overlapping Spironolactone Dosing in Primary Aldosteronism and Resistant Essential Hypertension

    The Journal of Clinical Hypertension

    Volume 14, Issue 10, October 2012, Pages: 732–734, Joel Handler

    Version of Record online : 3 AUG 2012, DOI: 10.1111/j.1751-7176.2012.00693.x

  16. You have free access to this content
    Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: β-cyclodextrin complex

    British Journal of Clinical Pharmacology

    Volume 44, Issue 1, July 1997, Pages: 35–39, A. Z. M. Abosehmah-Albidy, P. York, V. Wong, M. S. Losowsky and H. Chrystyn

    Version of Record online : 2 OCT 2003, DOI: 10.1046/j.1365-2125.1997.00626.x

  17. Influence of food on the bioavailability of spironolactone

    Clinical Pharmacology & Therapeutics

    Volume 40, Issue 5, November 1986, Pages: 531–536, Hans W P M Overdiek and Frans W H M Merkus

    Version of Record online : 1 NOV 1986, DOI: 10.1038/clpt.1986.219

  18. A preclinical pharmacokinetic and pharmacodynamic approach to determine a dose of spironolactone for treatment of congestive heart failure in dog

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 33, Issue 3, June 2010, Pages: 260–267, J. GUYONNET, J. ELLIOTT and V. KALTSATOS

    Version of Record online : 11 SEP 2009, DOI: 10.1111/j.1365-2885.2009.01130.x

  19. You have free access to this content
    Maximizing Diuretic Therapy in Resistant Hypertension

    The Journal of Clinical Hypertension

    Volume 9, Issue 10, October 2007, Pages: 802–806, Joel Handler Section Editor

    Version of Record online : 21 JUN 2011, DOI: 10.1111/j.1751-7176.2007.tb00009.x

  20. Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study

    Acta Obstetricia et Gynecologica Scandinavica

    Volume 74, Issue 10, October 1995, Pages: 803–808, Mingde Wang, Stefan Hammarbäck, Bengt-Åke Lindhe and Torbjörn Bäckström

    Version of Record online : 17 JAN 2011, DOI: 10.3109/00016349509021201